Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
subcutaneous
Pharma
Roche's bispecific Lunsumio goes subcutaneous
The new under-the-skin formulation reduces the Lunsumio administration time to about one minute compared with two to four hours for an infusion.
Angus Liu
Dec 22, 2025 10:15am
Argenx cans Vyvgart trials in thyroid eye disease over futility
Dec 15, 2025 10:00am
Halozyme CEO targets new deals as IRA uncertainty subsides
Oct 14, 2025 9:40am
Halozyme buys Elektrofi for up to $900M
Oct 1, 2025 2:36pm
Merck scores FDA approval for subcutaneous Keytruda
Sep 19, 2025 4:54pm
Roche's high-dose version of Ocrevus flunks phase 3 trial
Apr 2, 2025 3:26pm
